Zika News

 → October 24th, 2020

Eliminating fake zika news with pharmacist, nurse, and physician review.

Oct 23 • 12:10 pm CDT

The California Department of Public Health (CDPH) reported on October 1, 2020, the continual decline in travel-related Zika virus cases in 2020. The new report indicates only (3) Zika cases have been confirmed during 2020, which is a significant delines from the (41) Zika cases confirmed during 2019.

Thus far in California, Zika virus infections have been documented only in people who were infected while traveling to areas with ongoing Zika transmission, through sexual contact with an infected traveler, or through maternal-fetal transmission during pregnancy, said the CDPH.

Oct 21 • 11:47 am CDT

Researchers at the University of Maryland's new study shed new light on how Zika virus hijacks our own cellular machinery to break down an essential protein for neurological development, getting it to 'eat itself'. Mechanistically, the Zika virus NS2A interacts with KPNA2 and leads to the reduction of the KPNA2 protein level.

Published on September 28, 2020, this study found through the process known as autophagy, that KPNA2 is degraded via the CMA pathway and that ZIKV infection enhances KPNA2 degradation.

This process may contribute to the development of neurological or brain deficiencies and congenital birth defects in the newborns of infected pregnant women.

Oct 19 • 10:22 am CDT

A new article in The Lancet Infectious Diseases provided rates of vertical transmission and adverse outcomes from the Zika virus. Based on Bayesian latent class analysis of data from seven prospective studies done in different settings in the Americas, as well as in travelers and immigrants to Spain from the Americas.

These researchers found the markers of congenital Zika virus infection are estimated to be lowest in the first trimester of pregnancy and the susceptibility of the developing nervous system in an infant seemed to be the highest in the first trimester.

Oct 13 • 8:09 am CDT

UK-based Enesi Pharma and The University of Adelaide announced on September 22, 2020, that they are collaborating to accelerate the development of a novel needle-free vaccine for the Zika virus (ZIKV). This project will utilize a protective Zika virus DNA vaccine developed by the University of Adelaide, with Enesi Pharma’s ImplaVax technology.

The technology delivers a thermostable single solid dose implant containing the vaccine through the skin and into the tissue, without using a needle. Once inserted, the implant dissolves, releasing the active ingredient over time and inducing the desired immune response.

The University of Adelaide researchers will progress the pre-clinical work necessary to take the Zika vaccine to Phase 1 clinical trials. This work will be undertaken in collaboration with colleagues from the University of Wisconsin-Madison, Harvard University, and the Duke-National University of Singapore.

Oct 12 • 3:18 pm CDT

A new study published by PLOS on October 2, 2020, stated 'although the number of Zika virus (ZIKV) cases has declined following the 2015–2016 outbreak in the Americas, ZIKV remains a public health concern due to the potentially severe consequences of in utero exposure to the virus.'

Based on the current evidence available, these researchers said 'the clinical presentation of ZIKV infection in adolescents appears to be primarily mild and similar to the presentation in adults, with rare instances of severe complications and/or mortality. However, reliable estimation of the risks of ZIKV complications in these age groups is limited by the scarcity and quality of published data.'

The U.S. CDC states: There is no current local transmission of Zika virus in the continental United States, including Florida and Texas. But, Zika virus cases continue to be reported in Puerto Rico during 2020.

For more articles, try our search.